Full Press Release Details
Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis.
IRON
Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis
Key Takeaway: Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+45%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Cash runway
~48 mo
Minimal dilution risk
Lead asset
DISC-0974
Phase 2 · Inflammatory Bowel Disease (IBD)